# Timing of administration of prophylactic antibiotics for caesarean section: a systematic review and meta-analysis

# H Baaqeel,<sup>a</sup> R Baaqeel<sup>b</sup>

<sup>a</sup> College of Medicine–Jeddah, King Saud bin Abdulaziz University for Health Sciences and Department of OB/GYN, King Abdulaziz Medical City-WR, Jeddah, Saudi Arabia <sup>b</sup> St Joseph's Health Centre,University of Western Ontario, London, ON, Canada *Correspondence:* Hassan Baaqeel, P.O. Box 9515 (internal 6556), Jeddah 21423, Saudi Arabia. Email baaqeelhs@ngha.med.sa

Accepted 19 July 2012. Published Online 6 November 2012.

**Background** Prophylactic antibiotics reduce infectious morbidity from caesarean section. The timing of their administration, however, is a matter of controversy.

**Objectives** To examine maternal and neonatal infectious morbidity in women receiving preoperative prophylaxis compared with those receiving intraoperative administration.

Search strategy Medline, Embase, Current Controlled Trials and Cochrane Central were searched from their inception dates to December 2011.

**Selection criteria** Randomised controlled trials of a single dose of any antibiotic comparing preoperative with intraoperative administration were selected.

**Data collection and analysis** Trial characteristics, outcomes and quality measures, based on the Cochrane tool for risk of bias, were independently extracted. The random effect model of DerSimonian and Laird to estimate relative risks (RRs) for maternal and neonatal outcomes was used.

**Main results** Six trials met the inclusion criteria, reporting on 2313 women and 2345 newborns. Preoperative administration was

associated with a significant 41% reduction in the rate of endometritis compared with intraoperative administration (RR 0.59; 95% confidence interval [95% CI] 0.37–0.94;  $I^2$  0%). In the preoperative group, there were nonsignificant reductions in the rates of wound infection (RR 0.71; 95% CI 0.44–1.14;  $I^2$  0%), maternal febrile morbidity (RR 0.94; 95% CI 0.46–1.95;  $I^2$  0%), neonatal sepsis (RR 0.81; 95% CI 0.47–1.41;  $I^2$  0%), neonatal septic work-up (RR 0.93; 95% CI 0.71–1.21;  $I^2$  0%) and neonatal intensive-care unit admission (RR 0.92; 95% CI 0.65–1.28;  $I^2$  0%). There were nonsignificant increases in the rates of maternal pyelonephritis (RR 1.09; 95% CI 0.49–2.43;  $I^2$  0%) and neonatal pneumonia (RR 3.36; 95% CI 0.55–20.47;  $I^2$  0%).

**Conclusions** Compared with intraoperative administration, preoperative antibiotics significantly reduce the rate of endometritis. The lack of neonatal adverse effects should be cautiously interpreted given the limited power of the trials to detect such effects.

**Keywords** Caesarean section, intraoperative, preoperative, prophylactic antibiotics, timing.

Please cite this paper as: Baaqeel H, Baaqeel R. Timing of administration of prophylactic antibiotics for caesarean section: a systematic review and meta-analysis. BJOG 2013;120:661–669.

# Introduction

#### Rationale

The beneficial effect of prophylactic antibiotics in reducing the occurrence of infectious morbidity from caesarean section, whether elective or emergency, is well established.<sup>1</sup> A single dose of first-generation cephalosporin is as effective as multiple doses of broad-spectrum agents.<sup>2</sup> Prophylactic antibiotics for caesarean section are commonly used worldwide, and in most institutions a single dose is administered, generally after clamping of the umbilical cord.<sup>3,4</sup> However, a recent survey (published in 2011) of maternal and fetal medicine physicians in the USA revealed that 84% of those who responded (the response rate was 25%) used preoperative administration.<sup>5</sup> The effectiveness of prophylactic antibiotics depends on their presence in effective concentrations throughout the operative period. Classen et al.<sup>6</sup> found that administration of prophylactic antibiotics within a 2-hour period preoperatively was associated with the lowest surgical wound infection rate. Because of concerns about unnecessary fetal exposure, masking of fetal infection, increases in neonatal septic

work-up and the emergence of resistant strains when prophylactic antibiotics are given preoperatively, it is a common obstetric practice to administer prophylactic antibiotics after cord clamping. After administration of a 1g preoperative dose (0.5-6 hours) for elective caesarean section, the cefazolin concentration in maternal and fetal blood, as well as amniotic fluid, was found to be equal to or greater than the mean concentration inhibiting 90% of group B streptococcus strains.<sup>7</sup> Concerns about the increasing use of intrapartum antibiotic prophylaxis (IAP) to prevent neonatal group B streptococcal sepsis, particularly in North America, has led to some publications on the neonatal impact of such practices. The use of IAP was associated with reduced initial bacterial colonisation by Clostridium in the antibiotic-exposed infants, and did not promote colonisation by  $\beta$ -lactam-resistant bacteria.<sup>8</sup> Infants whose mothers received IAP were not more likely to undergo invasive procedures or to receive antibiotics.9 Conflicting results were reported for neonatal sepsis. Two studies, a large historical cohort study of 17 187 infants and a small case-control study of 132 infants, reported similar rates of neonatal sepsis among IAP-exposed and non-exposed neonates,<sup>10,11</sup> whereas two other studies, a retrospective review of 35 women and a study in which 27 women were prospectively followed, showed an increased rate of non-streptococcal organisms resistant to ampicillin in neonates exposed to IAP compared with those who were not exposed.<sup>12,13</sup> In utero exposure to antibiotics has been linked to development of allergic diseases in infancy.<sup>14</sup> Long-term effects of fetal exposure to antibiotics are beyond the scope of this review. Given that preoperatively administered antibiotics are associated with the lowest rate of surgical site infection and that, from a practical point of view, administration of the antibiotic preoperatively is less likely to be overlooked than after cord clamping, especially if intraoperative complications develop, preoperative administration seems more rational. The conflicting reports about the neonatal impact of the timing of prophylactic antibiotic administration prompted us to undertake this systematic review. While our review was in preparation, Costantine et al.<sup>15</sup> published a systematic review on the timing of the administration of prophylactic antibiotics in caesarean section. Our review updates the information contained in the Costantine et al. review.

#### Objectives

To examine whether there are differences in the rates of maternal and neonatal infectious morbidity, we reviewed randomised controlled trials that compared a single dose of any antibiotic administered preoperatively with a single dose of the antibiotic administered intraoperatively at or after clamping of the umbilical cord in women undergoing caesarean section.

# Methods

#### Protocol and registration

The search strategy, inclusion criteria and methods of analysis were specified in advance in a protocol that used the Cochrane Collaboration format but was not registered with any entity. The PRISMA Statement<sup>16</sup> was followed in this review.

#### Eligibility criteria

The eligibility criteria for the inclusion of work in the review were as follows.

Type of study: randomised controlled clinical trials investigating the timing of administration of prophylactic antibiotics in women undergoing caesarean section.

Type of participants: women undergoing any type of caesarean section, whether elective or during labour, were considered.

Type of intervention: trials comparing a single dose of any antibiotic administered preoperatively with a single dose of the same antibiotic administered intraoperatively at or after clamping of the umbilical cord.

Type of outcome measures: maternal outcomes included febrile morbidity, endometritis, wound infection and pyelonephritis. Neonatal outcomes included neonatal sepsis, neonatal septic work-up and neonatal intensive-care unit (NICU) admission. Trials that reported one or more of these outcomes were considered.

#### Information sources

Electronic databases that we searched (June 2007) included Medline (1966 to present), the Pre-Medline database, Embase (1980 to present), Current Controlled Trials and Cochrane Central. We also screened the reference lists of included trials and related review articles. No language or publication date limits were imposed.

#### Search

We used the following search terms and corresponding index terms: caesarean, cesarean, caesarean section, cesarean section, caesarean delivery, cesarean delivery, abdominal delivery, antibiotics, antimicrobials, prophylaxis and prophylactic antibiotics. The operators 'OR' and 'AND' were used to combine these terms. The final results were limited to clinical trials. An example of a midline search strategy is shown in the Supplementary material, Appendix S1.

#### Study selection

Both authors screened the titles and abstracts of the identified studies independently to exclude duplicates, letters to editors, editorials, review articles, retrospective studies and studies unrelated to the review question. The full text of the studies was obtained when titles or abstracts did not contain enough information. Remaining potentially eligible studies were retrieved for detailed evaluation. Eligibility criteria were applied independently by both authors to identify final eligible studies. Disagreement was resolved by discussion.

## Data collection process

Each reviewer, independently, extracted data from each included study using a predesigned data extraction form. Discrepancies were resolved by both authors checking the study against the form. Authors were contacted for missing data.

# Data items

Information was extracted from each study on: (1) characteristics of the participants, including type of caesarean section and the inclusion and exclusion criteria of the trial; (2) the type of intervention, including the type, dose, route of administration and timing of antibiotic administration; (3) the type of outcome measures, with their definition as reported in each study, including maternal febrile morbidity, wound infection, endometritis, pyelonephritis, neonatal sepsis, neonatal septic work-up, NICU admission and other outcomes reported in the trials.

## Risk of bias in individual studies

To assess the risk of bias in the included studies, both authors independently determined the adequacy of randomisation, concealment of allocation and blinding, and the extent of loss to follow up. Any disagreement was resolved by discussion.

#### Summary measures

Quantitative analyses were performed by computing relative risks (RRs) and their 95% confidence intervals (95% CIs) for dichotomous outcome variables. For continuous outcome variables a mean difference was calculated.

# Synthesis of results

A pooled estimate of outcomes was computed using the more conservative DerSimonian and Laird random effects model. We tested for statistical heterogeneity using the conventional Cochrane's Q test which is based on the chi-square test,  $I^2$  and tau-square tests. The quality of evidence for each outcome was graded using GRADEPRO.<sup>17</sup>

# Risk of bias across studies

The possibility of publication bias was assessed, when applicable, using a funnel plot of the effect of each trial against its standard error, and any asymmetry was checked using an adjusted rank correlation test<sup>18</sup> and the regres sion-based assessment of this asymmetry as described by Egger et al.<sup>19</sup> All analyses were performed using REVIEW MANAGER

5,<sup>20</sup> and for publication bias tests META-ANALYSIS MADE EASY (MIX) was used.<sup>21,22</sup>

### Additional analysis

Sensitivity analysis was performed if a study was determined to have an intermediate or high likelihood of bias that may influence the pooled estimates of the outcome of interest.

## Results

#### Study selection

The combined yield of the search of all the sources was 903 citations. Initial screening identified a total of 376 as duplicates, letters or editorials. Figure 1 depicts a flow chart for study selection from the remaining 527 citations. An ongoing trial was identified through the National Institute of Health's Clinical Trials Registry that was registered in August 2005 but terminated in September 2006 without publishing any report.<sup>23</sup> Six studies met the inclusion criteria so were included in the meta-analysis.<sup>24–29</sup>

#### Study characteristics

All six studies were randomised controlled trials. Four studies were from the USA, one was from Turkey<sup>27</sup> and one was from Austria.<sup>29</sup> Two studies were limited to emergency caesarean section<sup>24,25</sup> and the remaining four were limited to elective caesarean section<sup>26–29</sup>. Four of the studies used 1 g






Figure 1. Study selection flow chart.

Table 1. Characteristics	s of included studies	5
--------------------------	-----------------------	---

Source	No. of women	Type of CS	Primary outcome	Exclusion criteria	Antibiotic agent
Wax et al. 1997	90	Emergency	Endometritis or wound infection	Allergy, antibiotic use within 2 weeks, temperature $\geq$ 37.8°C, prophylaxis for GBS or SBE infections, IDDM, HIV infection, chronic glucocorticoid use, multiple gestation and gestation <37 weeks	Cefazolin 1 g
Thigpen et al. 2005	302	Emergency	Endometritis or wound infection	Allergy, antibiotic use within 2 weeks and acute chorioamnionitis	Cefazolin 2 g
Sullivan et al. 2007	357	Elective	Total maternal infectious morbidity	Allergy, antibiotic use within 1 week, age <18 years and gestational age <24 weeks	Cefazolin 1 g
Yildirim et al. 2008	389	Elective	Postoperative infections	Antibiotic use within 24 hours, fever on admission, DM, collagen vascular disease, immune system problems, chorioamnionitis, need for blood transfusion, ROM and gestational age <37 weeks	Cefazolin 1 g
Macones et al. 2011	434	Elective	Composites of maternal infection	Known fetal anomalies, exposure to antibiotics within 7 days, emergency CS, ROM greater than 18 hours and overt intrapartum infection requiring antibiotics	Cefazolin 1 g*
Witt et al. 2011	741	Elective; ROM and uterine contractions were allowed	Postoperative infections	Fever greater than 38°C, cephalosporin allergy, age <18 years and exposure to any antibiotic agent within 1 week before delivery	Cefazolin 2 g**

CS, caesarean section; DM, diabetes mellitus; GBS, group B streptococcus; HIV, human immunodeficiency virus; IDDM, insulin-dependent diabetes mellitus; ROM, rupture of membranes; SBE, subacute bacterial endocarditis.

\*Subjects allergic to penicillin received clindamycin 900 mg. Over 90% were reported to have received cefazolin.

\*\*The trial had a third placebo arm.

cefazolin and two used 2 g.<sup>25,29</sup> In all the studies the primary outcome of maternal infectious morbidity was used for the power calculation. Table 1 shows the characteristics of the included studies.

#### Risk of bias within studies

Assessment of risk of bias within studies is shown in Table 2. The included trials were of good methodological quality except for the trial by Yildirim et al.<sup>27</sup> Insufficient details were given to enable assessment of blinding at all levels. The authors stated:

Four hundred women who fulfilled the inclusion criteria were randomly (two parts, block random using sealed, sequentially distributed envelopes to which the letters A and B had been allocated: the letter A to the antibiotic prophylaxis before skin incision group and the letter B to the antibiotic prophylaxis after clamping umbilical cord group; the patients chose the envelopes which were opened by the investigator, and according to the letters, the group of patients were determined) divided into two groups.

From the published report, it appears that there was no blinding.

# Results of individual studies

The six included trials recruited a total of 2313 women and 2345 neonates. The definitions of outcomes were basically similar in all trials when reported. The breakdown of neonatal outcome was not sufficiently detailed in two trials.<sup>28,29</sup> One trial reported outcomes in percentages or mean values and lumped suspected cases of sepsis together without reporting how many had been confirmed. The other trial reported that neonatal outcomes were similar among groups without providing actual rates. The corresponding authors were contacted. The missing data were provided by one of them.<sup>29</sup> Individual trial results in a forest-plot format are shown for the outcomes endometritis, wound infection, pyelonephritis and total maternal infectious morbidity in Figure 2, whereas neonatal sepsis, neonatal septic work-up, NICU admission and neonatal pneumonia are shown in Figure 3. There was no evidence of heterogeneity in any of the above-mentioned analyses.

Maternal febrile morbidity was reported by two trials,<sup>27,28</sup> both of which showed a nonsignificant reduction (RR 0.94; 95% CI 0.46–1.95;  $I^2$  0%; forest plot not shown).

Maternal septic thrombophlebitis and maternal pneumonia or respiratory infections were studied in two

. . . .

Trial	Randomisatio	n		Bli	nding		Loss to follow-up
	Method	Concealment	Patient	Provider	Data collector	Outcome assessor	
Wax et al. 1997	Computer-generated	Yes	Yes	Yes	Yes	Yes	6/90 (6%) at 2 weeks 14/90 (15%) at 6 weeks
Thigpen et al. 2005	Computer-generated	Yes	Yes	Yes	Yes	Unclear	44/346 (13%) at 6 weeks
Sullivan et al. 2007	Random tables	Yes	Yes	Yes	Yes	Unclear	8/357 (2%) at 6 weeks
Yildirim et al. 2008	No details except 'two parts block randomisation'	Yes	In	sufficient de	tails. Probabl	y no.	11/400 (3%) at 6 weeks
Macones et al. 2011	No details except 'permuted blocks'	Probably yes	Yes	Yes	Yes	Yes	None
Witt et al. 2011	Computer-generated	Yes	Yes	Yes	Yes	Yes	32/741 (4.3%) at 4 weeks
Outc		Events / Total After cord		k Lower Upp		Risk ratio and	<u>195% CI (Random)</u>

#### Table 2. Risk of bias within studies

Double stration

- · ·




Figure 2. Forest plot showing results of the meta-analysis for maternal outcomes.

trials,<sup>24,27</sup> with no events occurring in either trial. Neonatal meningitis was addressed in two trials,<sup>24,25</sup> with no events occurring in either of them. The Thigpen et al. trial<sup>25</sup> reported one case of neonatal viral syndrome in the preoperative group, which was not significantly different from the intraoperative group (RR 2.9; 95% CI 0.1-71.2).

The length of stay in the NICU in days was reported by three trials.<sup>26–28</sup> There was a significant heterogeneity among the three trials  $(I^2 = 97\%)$ . A sensitivity analysis was performed by omitting the trial with questionable blinding. The degree of heterogeneity improved to an  $I^2$  of 43%. Therefore, this outcome was not considered any further.

10

100

Outcome	Study	Events	/ Total				
		Preop	After cord clamping	Risk ratio	Lower limit	Upper limit	
Neonatal pneumonia	Thigpen et al. 2005	1/153	0/149	2.922	0.120	71.165	
	Wax et al. 1997	2/49	0/41	4.200	0.207	85.081	
	Witt et al. 2011	1/370	0/371	3.008	0.123	73.603	
	Total	4/572	0/561	3.361	0.552	20.470	
Neonatal sepsis	Sullivan et al. 2007	6/185	7/194	0.899	0.308	2.625	
	Thigpen et al. 2005	7/153	7/149	0.974	0.350	2.709	
	Yildirim et al. 2008	9/201	13/198	0.682	0.298	1.559	
	Total	22/539	27/541	0.814	0.469	1.412	
Neonatal septic workup	Macones 2011	19/217	19/217	1.000	0.545	1.836	
	Sullivan et al. 2007	35/185	36/194	1.020	0.670	1.551	
	Thigpen et al. 2005	11/153	14/149	0.765	0.359	1.631	
	Wax et al. 1997	6/49	2/41	2.510	0.535	11.775	
	Yildirim et al. 2008	23/201	30/198	0.755	0.455	1.253	
	Total	94/805	101/799	0.929	0.714	1.208	
NICU admissions	Macones 2011	7/217	8/217	0.875	0.323	2.371	
	Sullivan et al. 2007	25/185	33/194	0.794	0.492	1.283	
	Thigpen et al. 2005	14/153	8/149	1.704	0.737	3.943	
	Witt et al. 2011	10/370	10/371	1.003	0.422	2.381	
	Yildirim et al. 2008	4/201	7/198	0.563	0.167	1.893	
	Total	60/1126	66/1129	0.917	0.654	1.284	
	Heterogeneity: Neonatal pneumonia $\tau$ Neonatal sepsis $\tau^2 = 0$ Neonatal septic workup NICU admission $\tau^2 = 0$	$0.00; \chi^2 = 0.3$ $\tau^2 = 0.00; \chi^2 = 0.00$	3, df = 2 ( $P$ = χ <sup>2</sup> = 2.73, df =	0.85); l <sup>2</sup> = 4 ( <i>P</i> = 0.	= 0% 60); l <sup>2</sup> = 0		0.01

Risk ratio and 95% CI (Random)




Figure 3. Forest plot showing results of the meta-analysis for neonatal outcomes.

#### Synthesis of results

Data on endometritis, wound infection, pyelonephritis and total maternal infectious morbidity were available from all six included trials (2313 women); on maternal febrile morbidity from two trials (823 women); on neonatal sepsis, neonatal septic work-up and NICU admission from five trials (1911, 1604 and 2255 newborns, respectively), and on neonatal pneumonia from three trials (1133 newborns).

Preoperative administration of prophylactic antibiotics was associated with a significant 41% reduction in the rate of endometritis (RR 0.59; 95% CI 0.37-0.94) and a significant 29% reduction in the rate of total maternal infectious morbidity (RR 0.71; 95% CI 0.52-0.98) compared with intraoperative administration. In the preoperative administration group, there were nonsignificant reductions relative to the intraoperative administration group in the rates of wound infection (RR 0.71; 95% CI 0.44-1.14), maternal febrile morbidity (RR 0.94; 95% CI 0.46-1.95), neonatal sepsis (RR 0.81; 95% CI 0.47-1.41), neonatal septic work-up (RR 0.93; 95% CI 0.71-1.21) and NICU admission (RR 0.92; 95% CI 0.65-1.28). There was a nonsignificant increase in the rate of maternal pyelonephritis (RR 1.09; 95%) CI 0.49-2.43) in the preoperative group. There was also a nonsignificant increase in the rate of neonatal pneumonia (RR 3.36; 95% CI 0.55-20.47) in newborns whose mothers received antibiotics preoperatively. Table 3 shows a summary of the findings, including the quality of the body of evidence, using GRADEPRO.<sup>17</sup> For all the outcomes reported, the quality of evidence was downgraded to moderate because of imprecision. Imprecision is judged on the bases of optimal information size and the width of the CI. Optimal information size is a sample size calculation to determine whether a trial is sufficiently powered to show a 25% reduction or increase in the risk of the outcome from the median of baseline risks for the included trials. None of the reported outcomes met the optimal information size criterion.

#### Risk of bias across studies

As only six trials were included in the meta-analysis, assessment of the possibility of publication bias using a funnel plot and tests of asymmetry are not reported.

#### Additional analysis

Because of the possible lack of blinding in the trial carried out by Yildirim et al.,<sup>27</sup> we conducted a sensitivity analysis of the related outcomes, omitting this trial. The pooled estimate and its 95% CI did not change appreciably in either direction or significance.

# Discussion

#### Summary of evidence

While this review was in preparation, another systematic review by Costantine et al.<sup>15</sup> addressing the same question, which included three randomised trials and two

			Quality assessment	nt			No. of patients	atients		Effect	Quality	Importance
No. of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecisiony	Other considerations	Preoperative	After cord clamping	Relative (95 % Cl)	Absolute		
Endometritis (follow up 1–6 weeks)	ow up 1–6 wee	iks)										
6	Randomised	No serious	No serious	No serious	Serious <sup>1</sup>	None	27/1158	47/1155	RR 0.59	17 fewer per 1000	0990	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(2.3%)	(4.1%)	(0.37–0.94)	(from 2 fewer to 26 fewer)	Moderate	
Wound infection (follow up 1–6 weeks)	(follow up 1-6	weeks)										
9	Randomised	No serious	No serious	No serious	Serious <sup>3</sup>	None	28/1158	40/1155	RR 0.71	10 fewer per 1000	0@@@	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(2.4%)	(3.5%)	(0.44–1.14)	(from 19 fewer to 5	Moderate	
Pyelonephritis (follow up 1–6 weeks)	llow up 1–6 we	seks)								more)		
. 9	Randomised	No serious	No serious	No serious	Serious <sup>4</sup>	None	13/1158	12/1155	RR 1.09	1 more per 1000	0000	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(1.1%)	(1%)	(0.49–2.43)	(from 5 fewer to 15	Moderate	
										more)		
Neonatal sepsis (follow up 1–6–weeks)	follow up 1–6–v	weeks)										
5	Randomised	No serious	No serious	No serious	Serious <sup>5</sup>	None	22/958	27/953	RR 0.81	5 fewer per 1000	0@@@	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(2.3%)	(2.8%)	(0.47–1.41)	(from 15 fewer to	Moderate	
Neonatal septic work-up (follow up 1–6 weeks)	ork-up (follow	up 1–6 weeks)								12 more)		
5	Randomised	No serious	No serious	No serious	Serious <sup>6</sup>	None	94/805	101/799	RR 0.93	9 fewer per 1000	0888	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(11.7%)	(12.6%)	(0.71–1.21)	(from 37 fewer to	Moderate	
Neonatal pneumonia (follow up 1–6 weeks)	nia (follow up	1–6 weeks)								27 more)		
	Randomised	No serious	No serious	No serious	Serious <sup>7</sup>	None	4/572	0/561	RR 3.36	I	0000	Critical <sup>2</sup>
	trials	risk of bias	inconsistency	indirectness			(0.7%)	(%0)	(0.55–20.47)		Moderate	
ICU admission												
5	Randomised	No serious	No serious	No serious	Serious	None	60/1126	66/1129	RR 0.92	5 fewer per 1000	0888	Important <sup>z</sup>
	trials	risk of bias	inconsistency	indirectness			(5.3%)	(5.8%)	(0.65–1.28)	(from 20 fewer to 16 more)	Moderate	
<sup>1</sup> OIS (Optimal Information Size) of 13256 not met. <sup>2</sup> Patient oriented outcome	mation Size) of 1.	3256 not met.										
<sup>3</sup> OIS of 9444 not met and CI include no effect.	net and CI include	e no effect.										
<sup>4</sup> OIS of 59370 not met and CI include no effect. <sup>5</sup> OIS of 11796 not met and CI include no effect.	met and CI inclue	de no effect. de no effect										
<sup>6</sup> OIS of 4292 is not met and CI include no effect.	met and CI inclu	ude no effect.										
<sup>7</sup> OIS of 67236 is not met and Cl include no effect. Bolic of 11526 is not mot and Cl include no official	t met and Cl inc	clude no effect.										
און לו סכב ו דו כוט־	01 met מווע כו ווור	ciude no enect.										

nonrandomised studies, was published in 2008. Three more trials have been published since the publication of that review. Our meta-analysis was discordant in the point estimates but not significantly different from Costantine et al.<sup>15</sup> for the neonatal septic work-up (their RR 1.0; 95% CI 0.70-1.42, our RR 0.93; 95% CI 0.71-1.21) and NICU admission (their RR 1.07; 95% CI 0.51-2.24, our RR 0.92; 95% CI 0.65-1.28). The numbers of participants in their review for these two outcomes were 771 and 681 respectively, whereas the corresponding newborns, numbers of participants in our review were 1911 and 2255, respectively. Therefore, the discordance is probably attributable to sample size. The effectiveness of prophylactic antibiotics in caesarean section to reduce the risk of maternal infectious morbidity is well established.<sup>1,2</sup> This effectiveness is based on a large number of trials using antibiotic administration after cord clamping. However, the effectiveness of prophylactic antibiotics depends on their presence in effective concentrations throughout the operative period, following administration within 2 hours of surgical incision.<sup>6</sup> Our review attempted to assess maternal and neonatal infectious outcomes for preoperative administration compared with administration after cord clamping. For maternal outcomes, there was a significant 41% reduction in the rate of endometritis and a significant 29% reduction in the rate of total maternal infectious morbidity when the antibiotic was administered preoperatively. There were nonsignificant reductions in the rates of wound infection and maternal febrile morbidity. For pyelonephritis, there was a nonsignificant increase with preoperative administration. For neonatal outcomes, there were nonsignificant reductions in the rates of neonatal sepsis, neonatal septic work-up and NICU admission, and a nonsignificant increase in the rate of neonatal pneumonia. Although combining similar trials of sufficiently good quality increases the power and precision of the pooled estimate, the number of neonates in the included trials (2345) may not be large enough to allow much confidence to be placed in the apparently reassuring results associated with preoperative administration. The evidence from this review is graded as moderate quality according to the Grade of Evidence Working Group criteria.<sup>30</sup> A grade of 'moderate' means that further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Tita et al.4 estimated that as many as 4800 caesarean deliveries would be needed to ascertain a 33% difference in neonatal sepsis with 80% power, assuming a baseline incidence of approximately 5%. However, recent studies on institutional policy changes from administration of antibiotic prophylaxis after cord clamping to preoperative administration confirmed the reduction in maternal infectious morbidity.<sup>31–33</sup> Of these, only the study by Owens et al.<sup>32</sup> reported on neonatal outcomes. Among 1979 neonates, preincision administration of antibiotics had no adverse effect on neonatal sepsis and neonatal septic work-up.

## Limitations

The number of trials included in our review was small, precluding the construction of meaningful funnel plots and the performance of statistical testing for publication bias, and this may be a limitation of our review.

# Conclusions

Compared with intraoperative administration, preoperative antibiotic administration significantly reduced the rate of endometritis. Other types of infectious maternal morbidity showed lower rates in the preincision administration group, but the differences did not reach statistical significance. Although this review revealed no significant neonatal adverse effects with preincision administration, these results should be interpreted with caution given the power limitation of the included trials.

# Implications for practice

Any consideration of a change in practice based on the evidence presented in this review should take into account the fact that the quality of the evidence for all reported outcomes is moderate.

# Disclosure of interest

No conflict of interest is declared.

# Contribution to authorship

BH conceived the review question, undertook the analysis and interpretation of data and drafted the manuscript. Both BH and BR were involved in acquisition of data, selection of studies, data extraction and trial quality assessment. BR contributed to the critical revision of the manuscript.

# Details of ethical approval

Ethical approval is not required as this is a systematic review of published manuscripts.

# Funding

No funding was received.

# Acknowledgements

We would like to acknowledge Dr Armin Witt, Division of Feto-Maternal Medicine, Department of Obstetrics and Gynecology, Medical University of Vienna, principal author for one of the included trials,<sup>29</sup> for providing breakdown data on neonatal outcome.

# **Supporting Information**

Additional Supporting Imformation may be foune in the online version of this article:

Appendix S1. Midline search strategy.

# References

- Smaill F, Hofmeyr GJ. Antibiotic prophylaxis regimens and drugs for cesarean section. The Cochrane Database of Systematic Reviews 1996; Issue 2: Art. No.:CD001136. DOI: 10.1002/14651858.
- 2 Hopkins L, Smaill F. Antibiotic prophylaxis regimens and drugs for cesarean section. The Cochrane Database of Systematic Reviews 1999, Issue 2. Art. No.:CD001136. DOI: 10.1002/14651858.
- **3** Festin M, Laopaiboon M, Pattanittum P, Ewens M, Henderson-Smart D, Crowther C. Caesarean section in four South East Asian countries: reasons for, rates, associated care practices and health outcomes. *BMC Pregnancy Childbirth* 2009;9:17–43.
- **4** Tita A, Rouse D, Blackwell S, Saade G, Spong C, Andrews W. Emerging concepts in antibiotic prophylaxis for cesarean delivery. a systematic review. *Obstet Gynecol* 2009;113:675–82.
- 5 Doss AE, Davidson JD, Cliver SP, Wetta LAL, Andrews WW, Tita ATN. Antibiotic prophylaxis for cesarean delivery: survey of maternal-fetal medicine physicians in the US. J Matern Fetal Neonatal Med 2012;25 1264–6.
- **6** Classen D, Evans R, Pestotnik S, Horn S, Menlove R, Burke J. The timing of prophylactic administration of antibiotics and the risk of surgical wound infection. *N Engl J Med* 1992;326:281–6.
- **7** Mitchell T, Pearlman M, Chapman R, Bhatt-Mehta V, Faix R. Maternal and transplacental pharmacokinetics of cefazolin. *Obstet Gynecol* 2001;98:1075–9.
- 8 Jaure'guy F, Carton M, Panel P, Foucaud P, Butel M, Doucet-Populaire F. Effects of intrapartum penicillin prophylaxis on intestinal bacterial colonization in infants. J Clin Microbiol 2004;42:5184–8.
- 9 Balter S, Zell E, O'Brien K, Roome A, Noga H, Schuchat A. Impact of intrapartum antibiotics on the care and evaluation of the neonate. *Pediatr Infect Dis J* 2003;22:853–7.
- **10** Edwards R, Jamie W, Sterner D, Gentry S, Counts K, Duff P. Intrapartum antibiotic prophylaxis and early-onset neonatal sepsis patterns. *Infect Dis Obstet Gynecol* 2003;11:221–6.
- 11 Schrag S, Hadler J, Arnold K, Martell-Cleary P, Reingold A, Schuchat A. Risk factors for invasive, early-onset escherichia coli infections in the era of widespread intrapartum antibiotic use. *Pediatrics* 2006;118:570–6.
- 12 Terrone D, Rinehart B, Einstein M, Britt L, Martin J, Perry K. Neonatal sepsis and death caused by resistant *Escherichia coli*: possible consequences of extended maternal ampicillin administration. *Am J Obstet Gynecol* 1999;180:1345–8.
- 13 Towers C, Carr M, Padilla G, Asrat T. Potential consequences of widespread antepartal use of ampicillin. Am J Obstet Gynecol 1998;179:879–83.
- **14** McKeever TMLS, Smith C, Hubbard R. The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database. *Am J Respir Crit Care Med* 2002;166:827–32.
- 15 Costantine M, Rahman M, Ghulmiyah L, Byers B, Longo M, Wen T, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. Am J Obstet Gynecol 2008;199:301–6.

- **16** Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med* 2009;151: 264–9.
- 17 Brozek J, Oxman A, Schünemann H. GradePro[program] V, 3.6. 2008.
- **18** Begg C, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50:1088–101.
- **19** Egger M, Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- **20** Review Manager (RevMan) [program]. 5.0.21 version. Copenhagen, 2008.
- 21 Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. *BMC Med Res Methodol*. 2006;6: doi:10.1186/ 1471-2288-6-50.
- 22 Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. MIX: comprehensive free software for meta-analysis of causal research data. Version 1.7. [http://mix-for-meta-analysis.info], 2008.
- **23** NCT00133029. The timing of prophylactic antibiotics in cesarean section and the risk of post-operative febrile morbidity. [http:// clinicaltrials.gov/ct2/show/NCT00133029].
- 24 Wax JR, Hersey K, Philput C, Wright MS, Nichols KV, Eggleston MK, et al. Single dose cefazolin prophylaxis for postcesarean infections: before vs after cord clamping. J Matern Fetal Med 1997;6:61–5.
- **25** Thigpen BD, Hood WA, Chauhan S, Bufkin L, Bofill J, Magann E, et al. Timing of prophylactic antibiotic administration in the uninfected laboring gravida: a randomized clinical trial. *Am J Obstet Gynecol* 2005;192:1864–8; discussion 1868–71.
- **26** Sullivan SA, Smith T, Chang E, Hulsey T, Vandorsten JP, Soper D. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized, controlled trial. *Am J Obstet Gynecol* 2007;196:455 e1–5.
- **27** Yildirim G, Gungorduk K, Guven H, Aslan H, Celikkol Ö, Sudolmus S, et al. When should we perform prophylactic antibiotics in elective cesarean cases? *Arch Gynecol Obstet* 2008;280:13–8.
- **28** Macones GA, Cleary KL, Parry S, Stamilio DM, Cahill AG, Odibo AO, et al. The Timing of antibiotics at cesarean: a randomized controlled trial. *Am J Perinatol* 2012;29:273–6.
- **29** Witt A, Petricevic L, Berger A, Germann P, Heinze G, Tempfer C. Antibiotic prophylaxis before surgery vs after cord clamping in elective cesarean delivery. *Arch Surg* 2011;146:1404–9.
- **30** Gordon HG, Andrew DO, Gunn EV, Regina K, Yngve F-Y, Pablo A-C, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924–6.
- **31** Kaimal AJ, Zlatnik MG, Cheng YW, Thiet MP, Connatty E, Creedy P, et al. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. *Am J Obstet Gynecol* 2008;199:310 e1–5.
- 32 Owens SM, Brozanski BS, Meyn LA, Wiesenfeld HC. Antimicrobial prophylaxis for cesarean delivery before skin incision. *Obstet Gynecol* 2009;114:573–9.
- **33** Young BC, Hacker MR, Dodge LE, Golen TH. Timing of antibiotic administration and infectious morbidity following cesarean delivery: incorporating policy change into workflow. *Arch Gynecol Obstet* 2012;285:1219–24.